# A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

> **NCT00306267** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 61 (actual)

## Conditions studied

- Anemia
- Cancer
- Epoetin Alfa

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00306267
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Study stopped as it would not address important survival concerns raised in other recently conducted clinical studies.
- **Last updated:** 2011-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306267, "A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00306267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*